GFC vs PRP for Knee Osteoarthritis — Patient Selection Matters More Than the Label

Knee osteoarthritis is often discussed as though every patient is choosing between only two options: tolerate the pain or undergo knee replacement. In reality, there is a large middle ground. Exercise, weight management where relevant, medicines, physiotherapy, activity modification and selected intra-articular treatments can all have a role before surgery becomes appropriate.

Two blood-derived injections increasingly discussed in India are platelet-rich plasma (PRP) and growth factor concentrate (GFC). Patients often ask which one is "better". That question sounds simple, but it can be misleading. The more useful questions are: What stage of arthritis does the patient have? What is causing the current limitation? What outcome is realistic? How strong is the evidence for the proposed treatment? And is an injection being used to improve symptoms in an appropriate knee, or simply to postpone a treatment that has already become necessary?

What PRP and GFC Actually Are

PRP is prepared from a patient's own blood. After processing, a platelet-enriched fraction is injected into the knee. Platelets contain numerous signalling proteins and growth factors that may influence inflammatory and healing pathways within the joint.

GFC is also an autologous blood-derived preparation. Depending on the preparation system, the process is designed to obtain a growth-factor-rich fraction after platelet activation while reducing cellular components in the final injectate.

Neither PRP nor GFC is a stem-cell treatment. Neither should be presented to patients as a guaranteed method of growing new cartilage, reversing established osteoarthritis or permanently avoiding knee replacement.

The Evidence Is Not Equally Mature

PRP currently has the broader evidence base. It has been studied in many randomized trials, systematic reviews and meta-analyses, although interpretation remains complicated by substantial variation in preparation methods, platelet concentration, leukocyte content, injection schedules and patient selection.

The American Academy of Orthopaedic Surgeons states that PRP may reduce pain and improve function in symptomatic knee osteoarthritis, but grades the recommendation as limited because of inconsistent evidence. More recently, the American Academy of Physical Medicine and Rehabilitation published detailed 2026 guidance supporting evidence-informed use of PRP in selected patients, while emphasizing disease severity, preparation characteristics, rehabilitation and informed consent.

GFC-specific evidence is considerably smaller. A 2024 systematic review identified only three eligible clinical studies and concluded that GFC appeared safe and potentially effective, while specifically calling for adequately powered multicentre randomized trials and direct comparisons with other orthobiologics. Additional randomized studies have since been published, including 2026 data in patients with moderate knee osteoarthritis. These are useful additions to the literature, but they do not yet give GFC the depth of independent evidence accumulated for PRP.

This distinction matters. A newer preparation can be promising without being proven superior.

What About Studies Suggesting GFC Is Better Than PRP?

Direct comparative research is beginning to appear. A 2026 study comparing GFC and PRP reported favourable clinical and biomarker outcomes with GFC. Such studies deserve attention, but one study should not be converted into a universal clinical claim.

Before concluding that one orthobiologic is superior, we need to consider sample size, patient population, exact preparation protocols, comparator formulation, blinding, follow-up duration, clinically meaningful effect sizes and independent replication. PRP itself is not one uniform product, and the same problem increasingly applies when broad labels such as GFC are used without sufficient product characterization.

For patients, the practical message is straightforward: treatment should not be chosen because one acronym sounds newer or more advanced.

Who May Reasonably Benefit From a Blood-Derived Injection?

The most sensible candidates are generally patients with symptomatic early-to-moderate knee osteoarthritis whose symptoms remain important despite an appropriate conservative programme, but whose knee has not reached a stage where arthroplasty is clearly the more predictable solution.

A typical assessment should look beyond the X-ray. Pain severity, walking tolerance, stair climbing, ability to rise from a chair, night pain, stiffness, range of movement, deformity, instability, body weight, muscle strength, activity expectations and previous treatment response all matter.

Radiographs remain important because they help define structural severity and alignment. But treatment should not be decided from an X-ray in isolation. Two patients with similar radiographs can have very different functional limitations and treatment priorities.

This is why patient selection is more important than simply choosing between GFC and PRP.

Who May Be Less Likely to Benefit?

An injection becomes less convincing when advanced structural disease is accompanied by severe functional loss, major deformity, substantial stiffness, instability, persistent rest or night pain, or progressive inability to perform basic daily activities.

In such circumstances, repeatedly offering injections can create false reassurance and delay a more definitive discussion.

There is also an important distinction between symptom improvement and structural restoration. A patient may experience meaningful pain relief without any evidence that lost cartilage has regenerated. Conversely, an imaging or biomarker change does not automatically prove a clinically important long-term modification of osteoarthritis.

The goal must therefore be defined before treatment. Is the objective to reduce pain, improve walking, make exercise possible, improve function for a period of time, or postpone surgery while the knee remains functionally acceptable? These are reasonable goals. "Regrow the knee" is not an evidence-based promise.

Where Injections Fit in the Larger Treatment Pathway

PRP or GFC should not replace the fundamentals of knee osteoarthritis care.

For many patients, treatment begins with education, appropriate exercise, quadriceps and hip strengthening, weight reduction when excess weight is contributing to joint load, modification of aggravating activities and appropriate analgesic or anti-inflammatory treatment when medically suitable. Physiotherapy can be particularly valuable when weakness, reduced movement or altered mechanics are contributing to disability.

An orthobiologic injection may then be considered as one component of this pathway in a selected patient. It should ideally create an opportunity for better movement and rehabilitation rather than becoming a stand-alone procedure repeated indefinitely.

The 2026 AAPM&R PRP guidance similarly places patient selection, disease severity and multimodal rehabilitation at the centre of responsible use.

GFC Versus PRP — How to Frame the Decision

When discussing these options, it helps to separate evidence from preference.

PRP has the advantage of a larger clinical literature and more mature professional guidance. Its weakness is heterogeneity: different PRP preparations may not be biologically equivalent, and protocols differ considerably.

GFC is attractive because of the way certain systems process and concentrate blood-derived growth factors while reducing cellular components. Early clinical studies are encouraging, including randomized trials. Its principal limitation is that the GFC-specific evidence base remains much smaller, with fewer independent and head-to-head studies.

Therefore, a patient should not be told that every GFC injection is better than every PRP injection, or vice versa. The decision should incorporate arthritis stage, clinical findings, previous treatment, product transparency, available evidence, cost, realistic expectations and patient preference.

8 Questions Every Patient Should Ask Before Agreeing to Treatment

Patients considering either injection should ask their clinician these practical questions before proceeding:

1. What stage of knee osteoarthritis do I have?
2. What improvement are we realistically trying to achieve?
3. Why is this injection appropriate for my knee rather than simply available at the clinic?
4. What preparation is being used and what evidence supports it?
5. What rehabilitation or exercise programme should accompany the injection?
6. How will we decide whether treatment has worked?
7. At what point would further injections no longer make sense?
8. If my arthritis is advanced, am I postponing a more predictable treatment without a clear benefit?

These questions protect patients from both extremes: dismissing potentially useful non-operative treatments too early and overselling them beyond the evidence.

When Surgery Enters the Conversation

Knee replacement should not be recommended merely because an X-ray looks severe. Equally, surgery should not be treated as a failure of regenerative medicine.

For patients with advanced osteoarthritis, substantial pain and meaningful functional limitation despite appropriate non-operative care, knee replacement can provide predictable improvement in pain and function. The decision is clinical and individual.

The role of GFC or PRP is therefore not to "defeat" knee replacement. Their role is to offer a reasonable symptom-management option for selected patients at an appropriate stage of disease. When the disease has progressed beyond that window, continuing injections simply because surgery is being avoided can become counterproductive.

🦴 The Bottom Line

The most important advance in orthobiologics may not be discovering a universally superior injection. It may be learning to use these treatments more precisely.

PRP currently has the stronger and broader evidence base. GFC has encouraging emerging evidence, including recent randomized and comparative studies, but still requires larger, independent, multicentre research before claims of superiority can be made confidently.

For an individual patient, the right question is not "Which injection is best?" It is: Given my arthritis stage, symptoms, function and goals, is an injection appropriate at all — and if so, which option has the most defensible evidence for my situation?

That is a more cautious message than many advertisements offer. It is also a more useful one.

#KneeOsteoarthritis #PRP #GFC #OrthopedicSurgery #HealthierTomorrow #KneePain #JointHealth #Orthobiologics #IndianHealth #KneeReplacement